N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Matthew McCallum; Anna De Marco; Florian Lempp; M. Alejandra Tortorici; Dora Pinto; Alexandra C Walls; Martina Beltramello; Alex Chen; Zhuoming Liu; Fabrizia Zatta; Samantha Zepeda; Julia di Iulio; John E Bowen; Martin Montiel-Ruiz; Jiayi Zhou; Laura Rosen; Siro Bianchi; Barbara Guarino; Chiara Silacci Fregni; Rana Abdelnabi; Shi-Yan Caroline Foo; Paul W Rothlauf; Louis-Marie Bloyet; Fabio Benigni; Elisabetta Cameroni; Johan Neyts; Agostino Riva; Gyorgy Snell; Amalio Telenti; Sean PJ Whelan; Herbert W Virgin; Davide Corti; Matteo Samuele Pizzuto; David Veesler.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-426475

Documentos relacionados

  1. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.
  2. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.
  3. Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.
  4. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations.
  5. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
  6. SARS-CoV-2 neutralizing antibody epitopes are overlapping and highly mutated which raises the chances of escape variants and requires development of broadly reactive vaccines.
  7. The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection.
  8. Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking.
  9. The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2.
  10. High-resolution map of the Fc functions mediated by COVID-19-neutralizing antibodies.